Medicine
Solifenacin 10 mg extended-release tablet
Solifenacin 10 mg extended-release tablet is a generic prescription medicine for oral use, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C…
Key facts
- Active ingredient (INN)
- Solifenacin
- Brand
- Sold under the generic name
- Strength
- 10 mg
- Dosage form
- Extended-release tablet
- Route
- Oral
- Packs
- 10 blister pack, 30 tablets, 90 tablets
- Manufacturer
- Glenmark PharmaceuticalsIndia
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 May 2019
- Identifiers
- RxCUI 477367, 477372DailyMed set ID 010c0657-c907-477f-8bd7-5d455a5f50ebNDC 68462-387Application ANDA209239
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 blister pack in 1 carton / 10 tablet, film coated, extended release in 1 blister pack | 68462-387-14 | Glenmark PharmaceuticalsIndia | 20 May 2019 |
| 30 tablet, film coated, extended release in 1 bottle | 68462-387-30 | Glenmark PharmaceuticalsIndia | 20 May 2019 |
| 90 tablet, film coated, extended release in 1 bottle | 68462-387-90 | Glenmark PharmaceuticalsIndia | 20 May 2019 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 19 November 2004 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Solifenacin
Clinical summary
Solifenacin is a cholinergic muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. It is available as tablets and extended-release tablets for oral use. MedsAcross supplies Solifenacin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about SolifenacinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- solifenacin succinate prescribing information (Macleods Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Solifenacin 10 mg extended-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.